Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic HER2-mutated NSCLC By Ogkologos - November 14, 2025 55 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SOHO-01 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR How Running and Training for a Marathon Helped Me Cope After... August 22, 2023 2023 ASCO Annual Meeting Research Round Up: Progress in Preventing Melanoma... September 12, 2023 Young Mom Battles Breast Cancer After Being Misdiagnosed with a Blocked... July 30, 2019 Cowboys Fan Battling Metastatic Breast Cancer Gets Surprise From Team’s Quarterback January 4, 2022 Load more HOT NEWS Alcohol linked to more than 740,000 new cancer cases globally in... Oncofertility: Creating a Bridge Between Cancer Care and Reproductive Health Findings from a Population-Based Study on Cancers Associated with Alcohol Consumption Breast Cancer Survivor Thanks Early Detection For Saving Her Life
